| Q40392328 | A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration |
| Q48123721 | A study of mutations in the c-kit gene of 32 dogs with mastocytoma |
| Q39686603 | Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines |
| Q36845216 | Advances in the diagnosis and management of cutaneous mast cell tumours in dogs |
| Q74419171 | Alteration of mast cell proliferation/apoptosis and expression of stem cell factor in the regression of mastocytoma--report of a case and a serial immunohistochemical study |
| Q39745856 | Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. |
| Q35017911 | Beyond H&E: integration of nucleic acid-based analyses into diagnostic pathology |
| Q39560865 | Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses |
| Q35740268 | Biology of gastrointestinal stromal tumors: KIT mutations and beyond |
| Q36857180 | Breed-predispositions to cancer in pedigree dogs. |
| Q38506396 | C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic. |
| Q21203579 | CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers |
| Q33719838 | Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11 |
| Q54626445 | Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. |
| Q34264313 | Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy |
| Q44876415 | Comparative Aspects of BRAF Mutations in Canine Cancers |
| Q36873386 | Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline |
| Q36615998 | Cutaneous mastocytosis with a mutation in the juxtamembrane domain of c-kit in a young laboratory beagle dog. |
| Q43413777 | Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis |
| Q28085473 | Dysregulation of tyrosine kinases and use of imatinib in small animal practice |
| Q33238296 | Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors |
| Q46017465 | Expression of KIT receptor in feline cutaneous mast cell tumors. |
| Q48441826 | Expression of c-kit proto-oncogene in canine mastocytoma: a kinetic study using real-time polymerase chain reaction |
| Q45178986 | Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog. |
| Q35217399 | FLT3: ITDoes matter in leukemia |
| Q40678754 | Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene |
| Q54785188 | Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. |
| Q37095268 | Generation and characterization of novel canine malignant mast cell line CL1. |
| Q39689493 | H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells |
| Q54587561 | Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. |
| Q39952949 | Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells |
| Q36078994 | Identification of the two KIT isoforms and their expression status in canine hemangiosarcomas |
| Q92594868 | Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing |
| Q33780403 | Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11. |
| Q35926007 | Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours |
| Q42471466 | Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. |
| Q46472931 | KIT-positive gastrointestinal stromal tumor in a 22-year-old male chimpanzee (Pan troglodites). |
| Q35909275 | Kinase inhibitors in leukemia |
| Q40610992 | Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. |
| Q35173798 | Mast cell tumors in the dog. |
| Q40801501 | Molecular cloning of canine IL-13 receptor alpha chain (alpha1 and alpha2) cDNAs and detection of corresponding mRNAs in canine tissues |
| Q37379320 | Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. |
| Q73287799 | Mutations of c‐kit at exons 17/13 are rare but clinically relevant in human subjects |
| Q39348704 | NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. |
| Q33979068 | New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors |
| Q35045459 | Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review |
| Q54712666 | Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. |
| Q47742852 | Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours |
| Q38033672 | Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy |
| Q44454011 | Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders |
| Q44524429 | Signal transduction by several KIT juxtamembrane domain mutations |
| Q39888618 | Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). |
| Q51769124 | Targeted knockdown of canine KIT (stem cell factor receptor) using RNA interference. |
| Q38255489 | The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells |
| Q35052156 | The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors |
| Q89786520 | The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs |
| Q55032145 | The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects. |
| Q51011082 | The use of COLD-PCR, DHPLC and GeneScanning for the highly sensitive detection of c-KIT somatic mutations in canine mast cell tumours. |
| Q43519030 | The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors |
| Q64930574 | Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. |